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TofacitinibStandard chemotherapy of tuberculosis (TB), which is caused by
infection withMycobacterium tuberculosis (Mtb) and which primari-
ly affects the lung, consists of a combination of antimicrobial drugs
(isoniazid, rifampin, ethambutol and pyrazinamide). Concomitant
administration of these antimicrobials helps eradicate active infection
and prevents disease relapse (Zumla et al., 2015). In most patients suf-
fering from drug-susceptible TB, strong adherence to treatment for at
least 6 months leads to cure of TB disease. However, poor compliance
with the prolonged treatment regime facilitates spread of infection, as
active TB patients expectorate bacteria. Prolonged treatment also pro-
motes the development of drug-resistant Mtb. Multidrug-resistant
(MDR)-TB is clinically difﬁcult to manage and accounted for 3.5% of
the 9 million new TB cases in 2013 and about 20.5% of previously treat-
ed TB patients (WHO, 2014). Shortening the length of TB chemotherapy
could thus limit spread of the disease and restrict emergence of drug re-
sistance. In this issue of EBioMedicine, Maiga et al. provide pre-clinical
evidence that Tofacitinib, an FDA-approved Janus kinase (JAK) inhibitor,
accelerates bacterial clearancewhen co-administeredwith canonical TB
chemotherapy.
Recent approaches toward more efﬁcacious interventions against
TB, including shortening the length of the chemotherapy, include
host-directed therapy (HDT) (Kaufmann et al., 2014). HDTs that
focus on modulation of inﬂammation comprise strategies to release
immune suppression and enhance anti-microbial mechanisms, or al-
ternatively, reduce inﬂammatory responses. Corticosteroids, TNF
blockers, statins, thalidomide analogues and inhibitors of phospho-
diesterases, cyclooxygenases and leukotrienes have been singled
out as potentially adjunctive to canonical chemotherapy (WallisDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.07.014.
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replication and destabilizes granulomas, thereby enhancing the tis-
sue penetrability of drugs effective against metabolically active bac-
teria. The rationale for dampening inﬂammation has been informed
by the efﬁcacy of most anti-mycobacterial drugs against actively rep-
licating Mtb and their limited activity against dormant bacilli.
Tofacitinib inhibits JAK3- and to a lesser extent JAK-2-mediated
phosphorylation of activated cytokine receptors and subsequently
limits responsiveness to pro-inﬂammatory cytokines (Pesu et al.,
2008). Tofacitinib is licensed for therapy of rheumatoid arthritis and ul-
cerative colitis. Moreover, similar to usage of TNF blockers, TB reactiva-
tion has been reported for this JAK inhibitor in cases of latent TB
infection (Winthrop et al., 2012) and in a mouse model of chronic
paucibacillary TB (Maiga et al., 2012). Pursuing observations that
Tofacitinib interferes with containment of TB (Maiga et al., 2012) and
based on pharmacokinetic studies, Maiga et al. evaluated efﬁcacy of
Tofacitinib as HDT for standard TB chemotherapy in different mouse
models (Maiga et al., in press). The authors showed that addition of
Tofacitinib to standard chemotherapy profoundly shortened time to
lung sterility in a chronic TB mouse model. Importantly, treatment
did not lead to isoniazid resistance and did not alter the time re-
quired to achieve relapse-free TB cure, which together are critical
for the design of novel, more efﬁcacious treatment regimens. These
ﬁndings strengthen the concept that strategies promoting “awaken-
ing” of dormantMtb are favorable for TB patients when applied con-
comitantly with chemotherapy. Many anti-inﬂammatory drugs are
clinically approved, and as such are a rationale choice for accelerating
the transition of preclinical ﬁndings to clinical trials. Design of novel
therapies based on repurposing drugs is particularly appealing for
protracted disease courses that require lengthy therapy, such as TB.
Furthermore, the authors provide proof of principle for successful JAK-
centered HDT of TB as an adjunct to standard TB chemotherapy. Ideal
for translational work, the therapy regimen used in murine studies by
Maiga et al. encompasses ﬁrst-line drugs as recommended for canonical
TB treatment. Advancing HDT to the arena of human clinical research
requires the addition of immunomodulatory compounds to standard
TB treatment. Reﬁnement of JAK inhibitors according to enzyme spec-
iﬁcities and pharmacological proﬁles could further enhance efﬁcacy
of a JAK-centered HDT in TB. Moreover, compounds with immuno-
modulatory activity similar to Tofacitinib could exhibit more pro-
nounced adjunctive effects in TB therapy.
Preclinical validation of Tofacitinib as adjunct to canonical chemother-
apy effectively consolidates a framework of anti-inﬂammatory HDT for
TB. Some questions remain, however. Shortening the length of treatmentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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strain for studies investigating efﬁciency of anti-mycobacterial drugs.
Tofacitinib administration toMtb-infected C3HeB/FeJ mice did not show
therapeutic effectiveness as observed in Balb/c animals. Notably,
C3HeB/FeJ mice developed lung lesions resembling human TB granulo-
mas, including hypoxia, necrosis and caseation (Driver et al., 2012). Dis-
crepant chemotherapeutical outcomes could reﬂect differences in
inﬂammatory patterns and lung pathology in the mouse models under
investigation. Future studies will clarify the mechanisms underlying di-
vergent therapeutic outcomes. Further elaboration of disease diversity
and how efﬁcacy of medication is affected accordingly, will advance
anti-TB therapy and contribute to our understanding of the complexity
of TB pathophysiology.
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